Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance Free

Multicellular organisms have developed highly efficient mechanisms of receptor-mediated cell communication to integrate and coordinate the function and proliferation of individual cell types. In this context, the PI3K/AKT/mTOR pathway plays a critical role in regulating multiple normal and abnormal biologic processes, including metabolism, migration, survival, autophagy, lysosome biogenesis, and growth (1). In response to different stimuli, including ligands of G protein–coupled receptors (GPCR) and tyrosine kinase receptors (TRK), PI3K catalyzes the formation of phosphatidylinositol (3,4,5)-trisphosphate (PIP₃), a membrane lipid second messenger that coordinates the localization and activation of a variety of downstream effectors, the most prominent of which are the isoforms of the AKT family (2). The AKTs possess a PH domain and conserved residues (Thr³⁰⁸ and Ser⁴⁷³ in Akt1, the most commonly expressed isoform in normal cells) which are critical for AKT activation. Specifically, AKT translocated to the plasma membrane in response to products of PI3K is activated by phosphorylation at Thr³⁰⁸ in the kinase activation loop and at Ser⁴⁷³ in the hydrophobic motif (1). The components of the PI3K pathway and the role of this pathway in disease have been reviewed (1, 3).

mTOR functions as a catalytic subunit in two structurally distinct multiprotein complexes, mTORC1 and mTORC2 (1, 4). mTORC1, a complex of mTOR, the substrate-binding subunit RAPTOR, GβL, and PRAS40, senses nutrients and growth factors. mTORC1 phosphorylates and controls at least two regulators of protein synthesis, the 40S ribosomal protein subunit S6 kinase (S6K) and the inhibitor of protein synthesis 4E-binding protein 1, referred as 4EBP1, which promote translation of cell growth proteins, including c-MYC and cyclin D. mTORC1 also plays a critical role in the regulation of cellular metabolism (5). The heterodimer of the tumor suppressor tuberous sclerosis complex 2 (TSC2; tuberin) and TSC1 (hamartin) represses mTORC1 signaling by acting as the GTPase-activator protein for the small G protein RHEB (RAS homolog enriched in brain), a potent activator of mTORC1 signaling in its GTP-bound state. Phosphorylation of TSC2 by AKT and/or ERK/p90RSK uncouples TSC1/TSC2 from RHEB, leading to RHEB-GTP accumulation and mTORC1 activation. The RAG GTPases activate mTORC1 in response to amino acids by promoting mTORC1 translocation to lysosomal membrane that contains RHEB-GTP (4). RAS-like (RAL) small GTPases, in their GTP-bound state, also promote mTORC1 activation through a pathway parallel to RHEB (6). Phosphatase and tensin homolog (PTEN) opposes PI3K by dephosphorylating PIP₃ to PIP₂ thereby inactivating AKT and mTOR signaling (7).

The PI3K/AKT/mTORC1 module is aberrantly activated in many human cancers and plays a pivotal role in insulin/insulin growth factor (IGF) receptor signaling. Inactivation of p53, as seen during the progression of approximately 50% of human malignancies, potently upregulates the insulin/IGFI/mTORC1 pathway (8). Consequently, mTORC1 and the upstream components of the cascade have emerged as attractive therapeutic targets in a variety of common malignancies (9).

Mounting evidence indicates that the mTORC1/S6K axis not only promotes growth-promoting signaling but also mediates potent negative feedback loops that restrain upstream signaling through insulin/IGF receptor and other TRKs in both normal and oncogene-transformed cells (Fig. 1). Suppression of these feedback loops by inhibitors of mTORC1/S6K causes compensatory overactivation of upstream signaling nodes, including PI3K, AKT, and ERK that potentially oppose the antiproliferative effects of the inhibitors and lead to drug resistance. To realize the therapeutic potential of targeting mTOR, it is necessary to elucidate the full spectrum of feedback loops that are unleashed by suppression of the PI3K/AKT/mTOR pathway. The detailed understanding of these feedback mechanisms will allow the design of rational combinations of therapeutic agents to overcome drug resistance produced by compensatory activation of upstream pathways and the identification of biomarkers to predict which patient will respond to them. The purpose of this article is to review negative feedback mechanisms that restrain signaling via upstream elements of the PI3K/AKT/mTOR pathway as well as mechanisms leading to the compensatory activation of other pro-oncogenic pathways, including MEK/ERK. The studies discussed here underscore the importance of unintended pathway activation in the development of drug resistance to clinically relevant inhibitors of mTOR, AKT, PI3K, or PI3K/mTOR.

The insulin receptor substrate (IRS) docking proteins, including IRS-1 and IRS-2, play a key role in insulin/IGF signaling through PI3K. These proteins are phosphorylated by these receptors at multiple Tyr residues that play a critical role in downstream signaling, including PI3K activation. The IRS family is also phosphorylated at multiple serine and threonine residues that attenuate signaling and promote degradation. As illustrated in Fig. 1, loop 1, activation of the mTORC1/S6K cascade inhibits IRS-1 function, including PI3K/AKT activation, following its phosphorylation at multiple residues, including Ser^636/639 by mTORC1 and Ser^{270/307/636/1001} by S6K (10). Accordingly, suppression of mTORC1 activity by rapamycin (sirolimus) and its analogs (rapalogs) prevents inhibitory phosphorylations mediated by mTORC1/S6K (11). Rapalogs, (e.g., RAD001/everolimus) which act as allosteric inhibitors of mTORC1 via FKBP-12 were the first generation of mTOR inhibitors to be tested as anticancer agents.

A prominent consequence of mTORC1/S6K inhibition by rapalogs in cells, preclinical cancer models, and clinical trials has been a striking increase in AKT phosphorylation at Thr³⁰⁸ by PDK1 and at Ser⁴⁷³ by mTORC2 (11–13). In this context, loss of PTEN expression which can potentiate feedback AKT phosphorylation in response to rapamycin is actually a marker of rapalog resistance rather than a biomarker for the use of mTORC1 inhibitors in human bladder cancer cells (14). mTORC2-mediated phosphorylation of AKT at Ser⁴⁷³ in response to rapamycin can be further enhanced by eliminating negative cross-talk from mTORC1/S6K (Fig. 1, loop 2). Specifically, Liu and colleagues reported that phosphorylation of SIN1, a specific component of mTORC2 also known as MAPK-associated protein 1, at Thr⁸⁶ and Thr³⁹⁸ suppresses mTORC2 kinase activity by dissociating SIN1 from mTORC2 (15). SIN1 phosphorylation, mediated by S6K in epithelial cells (AKT can also phosphorylate SIN1 in mesenchymal cells), inhibits not only insulin- or IGFI-mediated, but also platelet-derived growth factor (PDGF)- or EGF-induced AKT phosphorylation by mTORC2 (15). Thus, these findings reveal a novel negative feedback loop connecting mTORC1 and mTORC2 and an additional mechanism by which exposure to rapamycin enhances AKT phosphorylation at Ser⁴⁷³.

A recent study by Kim and colleagues (16) revealed that mTORC2 can also regulate the cellular level of IRS-1. These investigators found that despite phosphorylation at the mTORC1-mediated serine sites, inactive IRS-1 accumulated in mTORC2-disrupted cells. Defective IRS-1 degradation was due to diminished expression and phosphorylation of the ubiquitin ligase substrate-targeting subunit, FBW8 (16). mTORC2 stabilizes FBW8 by phosphorylation at Ser⁸⁶, allowing the insulin-induced translocation of FBW8 to the cytosol where it mediates IRS-1 degradation. Thus, mTORC2 negatively feeds back to IRS-1 via control of FBW8 stability and localization (Fig. 1, loop 3). These findings indicate that mTORC1 and mTORC2 cooperate in promoting IRS-1 degradation and imply that the potential therapeutic benefit of inhibiting mTORC1 with rapamycin is opposed by release of feedback inhibition of PI3K/AKT activation (11, 13), resulting in disease progression. Although rapalogs have been demonstrated to prolong overall survival of patients with metastatic renal cell carcinoma, the clinical antitumor activity of rapamycin analogs in many types of cancer has been rather limited. In some cases, mutated cancer genes can serve as biomarkers of response to targeted agents. So far, the use of PTEN, PI3K mutations, and AKT phosphorylation as biomarkers for predicting rapalog sensitivity has not been successful in clinical settings. In fact, as mentioned above, loss of PTEN expression may be a marker of rapalog resistance, at least in some cancer cells. It is likely that treatment with rapalogs not only interferes with feedback loops that restrain PI3K/AKT activation but also with other signaling pathways that can promote drug resistance, as discussed below.

In addition to the feedback loop that restrains PI3K/AKT activation, immunohistochemical analysis of biopsies of patients with breast cancer that were treated with the rapalog RAD001 (everolimus) revealed that there was a marked increase in ERK activation, i.e., ERK phosphorylated on the activation loop residues Thr²⁰² and Tyr²⁰⁴ (17). These results indicated that anticancer therapy with allosteric mTORC1 inhibitors can lead to activation of the ERK pathway, thus adding a new level of complexity to the previously described negative feedback loop involving mTORC1/PI3K/AKT. On the basis of experiments using inhibitors of PI3K (LY294002) and a dominant-negative form of RAS (RASN¹⁷), Carracedo and colleagues (17) concluded that ERK overactivation in response to rapamycin depended on the function of PI3K/RAS but the mechanism(s) was not defined. In all the experiments presented, the cells were exposed to the rapamycin for at least 24 hours (17). Thus, it is not clear whether the putative PI3K-dependent pathway is an acute effect of unleashing a rapid feedback loop or a slow feedback loop involving a transcriptional response (see below).

A recent study with breast cancer cells harboring PI3KCA mutant or HER2 amplification but without RAS mutations suggest a possible mechanism by which PI3K can lead to ERK pathway activation (18). Specifically, PI3K-mediated PIP₃ accumulation increased the activity of RAC1 (RAC1-GTP) via PIP₃-dependent RAC exchanger 1 (P-Rex1) and of its effector PAK1 leading to phosphorylation of RAF1 at the activating Ser³³⁸. These findings imply that robust PI3K-mediated RAC/PAK1 can enhance RAF stimulation and thereby promote MEK/ERK overactivation (Fig. 1). It will be of interest to determine whether rapamycin-induced ERK is correlated to P-Rex1 expression, RAC-GTP, and RAF Ser³³⁸ phosphorylation. A putative alternative pathway of PIP₃-dependent ERK activation involves the recruitment of the adaptor GRB2-associated binder 1 (GAB1) which in turn recruits GRB2–SOS, leading to RAS/RAF activation (19). In this context, it is also relevant that long-term exposure to rapamycin also initiates transcriptional upregulation of PI3K subunits, e.g., p85α and p110δ (20), potentially reinforcing the PI3K-mediated signaling to RAC/PAK1 and/or GAB1/GRB2/SOS which can lead to MEK/ERK overactivation in response to rapamycin.

Another mTORC1-mediated negative feedback loop restrains the expression of PDGF receptor (PDGFR). Activation of PI3K or AKT or deletion of PTEN in mouse embryonic fibroblasts suppresses PDGFR expression, whereas rapamycin increases PDGFR expression (21). In hepatocellular carcinoma cells, prolonged (>6 hours) treatment with rapamycin induced ERK signaling through increased expression and phosphorylation of PDGFRβ (22). The role of this PDGFRβ-dependent loop leading to ERK signaling in other cancer cells requires further experimental work. The remodeling of the signaling network in response to rapalogs is illustrated in Fig. 2A.

As discussed above, the potential anticancer activity of rapamycin (or analogs) can be counterbalanced by release of feedback inhibition of PI3K/AKT and ERK activation. Furthermore, rapamycin incompletely inhibits 4E-BP1 phosphorylation (23, 24). Specifically, most cells display a high basal level of 4E-BP1 phosphorylation at Thr^37/46 that is not further increased by growth factor stimulation nor inhibited by rapamycin (25). However, cell stimulation reduced the mobility of 4E-BP1 in SDS/PAGE, a response suggestive of increased phosphorylation at other sites. Indeed, growth factor stimulation of pancreatic cancer cells markedly stimulated 4E-BP1phosphorylation on Thr⁷⁰, a response blocked by treatment with rapamycin (25). These results revealed an unappreciated regulation of 4E-BP1 phosphorylation on different residues in response to external signals and demonstrate that rapamycin inhibits inducible but not constitutive 4E-BP1 phosphorylations. More studies are needed to determine whether 4E-BP1 is subject to constitutive and inducible phosphorylations at different sites in different cancer cells.

In an effort to target the mTOR pathway more effectively, novel ATP-competitive inhibitors of mTOR that act at its catalytic active site (active-site mTOR inhibitors) have been identified, including PP242 (26), Torin (27), KU63794 (28), and its analog AZD8055 (29). These compounds inhibit 4E-BP1 phosphorylation at rapamycin-resistant sites (e.g., Thr^37/46) and block AKT phosphorylation at Ser⁴⁷³, in line with the notion that mTORC2 is the major protein kinase that phosphorylates AKT at this residue. Active-site inhibitors proved more effective inhibitors of cell proliferation than rapamycin in a variety of model systems. However, active-site mTOR inhibitors also eliminate negative feedback loops that restrain PI3K activation and, consequently, their therapeutic effectiveness can also be diminished by activation of upstream pathways that oppose their antiproliferative effects (Fig. 2B). Specifically, active-site mTOR inhibitors enhance PI3K/PDK-dependent AKT phosphorylation at its activation loop (Thr³⁰⁸) and, consequently, these agents do not completely block AKT activity (30).

Surprisingly, short-term exposure of a variety of cell types, including human pancreatic cancer cells (25) and multiple myeloma cells (31), to active-site mTOR inhibitors, such as KU63794 or PP242, induced a striking overactivation of ERK. The mTOR inhibitors also induced MEK overactivation, as scored by assessing the phosphorylation of Ser²¹⁷ and Ser²²¹ in the MEK activation loop, and MEK inhibitors abrogated the overactivation of MEK. In contrast, treatment with rapamycin at concentrations that completely prevented the mTORC1/S6K axis, as scored by phosphorylation of S6K on Thr³⁸⁹ did not cause any change in ERK phosphorylation in cells harboring RAS mutations (25, 31). These results indicated that first and second generations of mTOR inhibitors promote overactivation of different upstream pro-oncogenic pathways in a cell context–dependent manner.

Further evidence supporting that active-site inhibitors enhance ERK overactivation through a PI3K-independent feedback loop was obtained by determining the effect of KU63794 or PP242 on ERK activity in multiple myeloma cells treated with wortmannin (31) or pancreatic cancer cells treated with A66, a selective inhibitor of the p110α catalytic subunit of PI3K (25). Inhibition of PI3K did not prevent enhancement of ERK activation in response to active-site mTOR inhibitors. These results identified a PI3K-independent feedback loop regulating the cross-talk between the mTOR and MEK/ERK pathways which is different from the loop previously identified with rapamycin (17). The remodeling of the signaling network in response to active-site mTOR inhibitors is illustrated in Fig. 2B.

The fact that PI3K and mTOR have high homology in their kinase domains has made possible the development of dual active-site inhibitors (PI3K/TOR-KIs), including NPV-BEZ235 (32), PKI-587 (33), and GDC-0980 (34). Additional PI3K/TOR-KIs that are being tested in preclinical and clinical trials include XL765, NVP-BKM120, XL147, SF1126, GSK2126458, VS-5584, and PF-04691502. As mentioned above, overactivation of the ERK pathway induced by active-site mTOR inhibitors is mediated through a PI3K-independent pathway (25, 31). Therefore, it could be expected that dual PI3K and mTOR inhibitors also promote ERK overactivation. In line with this prediction, our current studies demonstrate ERK overactivation in pancreatic cancer cells treated with multiple clinically relevant PI3K/TOR-KIs, including NPV-BEZ235, PKI-587, and GDC-0980 (H. P. Soares et al., unpublished). These results with dual PI3K and mTOR catalytic kinase inhibitors provide conclusive evidence identifying a novel PI3K-independent feedback loop that restrains the activity of the MEK/ERK pathway. The remodeling of signaling in response to active-site PI3K/mTOR inhibitors is illustrated in Fig. 3A.

A plausible mechanism by which active-site mTOR inhibitors or dual PI3K/mTOR inhibitors relieve a negative feedback on receptor tyrosine kinases that leads to RAF/MEK/ERK has been suggested by recent phosphoproteomic studies demonstrating that mTORC1 directly phosphorylates the adaptor protein growth factor receptor–bound protein 10 (GRB10) at multiple sites (35, 36). GRB10 is known to suppress signaling induced by insulin and IGFs (37) and mice lacking GRB10 are larger than normal and exhibit enhanced insulin sensitivity (38). In addition to inhibiting insulin/IGFI receptor tyrosine kinase activity by direct binding, GRB10 also mediates degradation of these receptors through ubiquitination (39). The phosphorylation of GRB10 by mTORC1 enhances its stability and capacity to inhibit insulin/IGF signaling. The sites phosphorylated by mTORC1 were mapped to Ser¹⁰⁴, Ser¹⁵⁰, Thr¹⁵⁵, Ser⁴²⁸, and Ser⁴⁷⁶ (35). While active-site mTOR inhibitors blocked phosphorylation of GRB10 at all five sites, rapamycin only prevented GRB10 phosphorylation at Ser⁴⁷⁶ (35). Therefore, GRB10, like 4E-BP1, is an mTORC1 substrate with both rapamycin-sensitive and -insensitive sites. As the phosphorylation of GRB10 potentiates its inhibitory activity on insulin/IGF receptor signaling, acute suppression of GRB10 phosphorylation at all sites (by direct mTOR inhibitors or dual PI3K/mTOR inhibitors) eliminates its ability to attenuate insulin/IGF signaling (Fig. 1, loop 4) thereby leading to MEK/ERK activation.

Another potential mechanism by which active-site mTOR or dual PI3K/mTOR inhibitors could promote MEK/ERK signaling is via enhanced EGFR activity. The EGFR tyrosine kinase activity and affinity for its ligand is known to be negatively regulated by PKCα via phosphorylation at Thr⁶⁵⁴ (40). Recent studies indicated that mTORC2 mediates PKCα phosphorylation of both the turn and hydrophobic motifs (41, 42). Interestingly, the mTORC2-dependent phosphorylation of PKCα plays an important role in its maturation, stability, and signaling (41, 42). It is plausible, therefore, that suppression of mTORC2-mediated posttranslational processing of PKCα interferes with negative feedback of PKCα on EGFR thereby leading to hyperactivation of EGFR and overactivation of ERK signaling in response to EGFR agonists or GPCR transactivation (43), as illustrated in Fig 1, loop 5.

A recent study examining the role of AKT in EGFR trafficking elucidated a novel negative feedback mechanism (44). Specifically, EGF-induced activation of AKT promotes progression of internalized EGFR through the early endosomes and EGFR degradation. In cells treated with inhibitors of PI3K or AKT, EGFR trafficking was impaired and accumulated in the early endosomes, resulting in increased ERK activation (44). It is conceivable that AKT inhibition interferes with this negative feedback loop (Fig. 1, loop 6) thereby promoting EGFR accumulation and enhanced ERK signaling in cells with a hyperactive EGFR signaling system. Accordingly, it will be of interest to determine whether EGFR inhibitors potentiate the inhibitory effects of AKT inhibitors.

In addition to MEK/ERK, dual PI3K/mTOR inhibitors can also induce compensatory activation of other signaling pathways that mediate resistance to these drugs. In triple-negative breast cancer (TNBC), a clinically aggressive subtype of breast cancer defined by lack of expression of estrogen and progesterone receptors and HER2 amplification, PI3K/mTOR inhibition induced feedback activation of JAK2/STAT5 and secretion of IL8 in cell lines and primary breast tumors (45). In TNBC, inhibition of JAK2 abrogated this feedback loop and combined PI3K/mTOR and JAK2 inhibition synergistically reduced cancer cell number and tumor growth (45).

It is pertinent that cross-talk between PI3K/AKT/mTOR and MEK/ERK pathways also functions in the opposite direction. Specifically, MEK inhibitors have been shown to induce PI3K/AKT activation via EGFR (46), thus revealing a negative feedback loop mediated by ERK phosphorylation of EGFR (e.g., at Thr⁶⁶⁹) that restrains PI3K/AKT activation and PIP₃ accumulation (47). This negative feedback (Fig. 1, loop 7) could also underlie the different responses of colon and melanoma cancer cells (both with BRAF V600E mutations) to BRAF inhibitors (48, 49). While melanomas are highly sensitive to BRAF inhibitors, colon cancers harboring the identical BRAF V600E mutation are resistant to these agents. Two elegant studies demonstrated that the drug resistance of colon cancer cells is due to increased expression and signaling of EGFR in these cells (48, 49). Previously, we mentioned that EGFR signaling is negatively regulated by PKCα (40). Interestingly, PKCα is expressed in melanoma (50) but decreased in most colorectal cancers (51), suggesting another mechanism by which EGFR signaling could be stronger in colon cancers following release of feedback inhibition. Consequently, release of feedback inhibition by BRAF inhibitors induces stronger EGFR activation in colon cells thereby recovering ERK pathway activation via alternative pathways (CRAF instead BRAF) as well as enhancing EGFR-induced PI3K/AKT signaling.

Another feedback loop could also involve the ERK-regulated p90RSK which has been shown to phosphorylate (at Ser¹¹⁰¹) and inhibit IRS-1 (52) and ERK-mediated feedback of RAS/RAF activation, for example, via phosphorylation of SOS (Fig. 1, loop 8). More recent work has demonstrated that MEK1 is an essential regulator of the lipid/protein phosphatase PTEN, through which it restrains PIP₃ accumulation and AKT signaling. MEK1 has been shown to be required for PTEN membrane recruitment as part of a ternary complex containing the multidomain adaptor MAGI1 (53). Complex formation depends on phosphorylation of MEK1 at Thr²⁹² by activated ERK. Consequently, ERK inhibition by MEK inhibitors prevents PTEN membrane recruitment, increasing PIP₃ accumulation and AKT activation (Fig. 1, loop 9).

Reciprocal feedback loops connecting PI3K/AKT/mTOR and MEK/ERK pathways provide further impetus for developing combination of inhibitors that cotarget both pathways. Indeed, phase I clinical trials cotargeting these pathways with MEK inhibitors plus PI3K/mTOR inhibitors are ongoing (e.g., Clinicaltrial.gov identifiers NCT01347866; NCT01390818). The remodeling of the signaling network in response to MEK inhibitors is illustrated in Fig. 3B.

In addition to ERK and AKT overactivation in response to acute mTOR pathway inhibition, a number of studies demonstrated that long-term treatment with PI3K, AKT, or PI3K/mTOR inhibitors induces a transcriptional response that also leads to drug resistance (54–59). The forkhead box O (FOXO) transcription factors, which include FOXO1, 3, 4, and 6 in mammals, are major downstream targets of the AKTs. The phosphorylation of FOXO by AKT creates docking sites for 14–3–3 proteins. The binding of 14–3–3 to FOXO promotes its translocation from the nucleus to the cytoplasm. Reciprocally, inhibition of AKT activity releases a feedback loop that promotes nuclear localization of the FOXO transcription factors (Fig. 1, loop 10). Nuclear FOXO family members stimulate transcription of several TRKs, including EGFR, IGFR, and insulin receptor in a spectrum of tumor cells (54). Furthermore, a recent study showed that FOXOs upregulated the expression of RICTOR, thereby enhancing mTORC2 and AKT phosphorylation at Ser⁴⁷³ (60), thus creating an amplification loop. At least in some cancer cells, FOXO-mediated transcription cooperates with enhanced cap-independent translation mediated by Pim-1 (58).

Accordingly, recent preclinical and clinical studies revealed that suppression of PI3K, AKT, or PI3K/mTORC1 initiates transcriptional responses that lead to the overexpression of TRKs or adaptor proteins, including HER3, IGFR, FGFR and in some cases, consequent enhancement of ERK. Dimerization of HER3 with EGFR or HER2 then promotes resistance to a number of inhibitors of PI3K signaling (61). Chronic exposure of HER2-positive breast cancer models to NPV-BEZ235 induced activation of HER family of receptors and adaptors leading to ERK overactivation, as shown by increased expression of HER3 and phosphorylation of HER2 and HER3 (56). In these breast cancer cells, ERK overactivation was completely prevented by inhibitors of MEK or HER2, suggesting clear combinatorial strategies to circumvent resistance to PI3K/AKT inhibition. Compensatory activation of HER3 and ERK has been corroborated in clinical samples following treatment with GDC-0068, an inhibitor of AKT catalytic activity (59). In contrast, treatment with a PI3K inhibitor (XL147) promoted expression of several TRKs but did not stimulate ERK overactivation (55). In ovarian cancer cells, NVP-BEZ235 also induces a program leading to expression of receptors and survival proteins, at least in part due to enhanced cap-independent translation, but do not appear to stimulate ERK signaling (57). In conclusion, treatment of a variety of tumor cells with inhibitors that block the PI3K/AKT/mTOR pathway at each level induces a concerted transcriptional response mediated, at least in part, by FOXO family members that oppose the anticancer effects of these agents. This gene expression loop should be distinguished from the rapid MEK/ERK overactivation induced by mTOR and dual PI3K/mTOR inhibitors in other cell types (25, 31). The FOXO-mediated transcriptional response on signaling in response to active-site mTOR inhibitors and dual PI3K/mTOR inhibitors are highlighted in Figs. 2 and 3.

Metformin (1,1-dimethylbiguanide hydrochloride) is the most widely prescribed drug for treatment of type 2 diabetes mellitus (T2DM) worldwide but its mechanism of action remains incompletely understood. At the cellular level, metformin indirectly stimulates AMP-activated protein kinase (AMPK) activation via inhibition of mitochondrial complex I (62), though other cellular mechanisms of action have been proposed, especially at high concentrations (63, 64). AMPK is a conserved regulator of the cellular response to low energy, and it is activated when the ATP concentration decreases and 5′-AMP and ADP concentrations increase. AMPK, a potent inhibitor of anabolic metabolism, is also implicated in the regulation of epithelial cell polarity (65). The tumor suppressor LKB-1/STK11 (Liver kinase B1/serine–threonine kinase; ref. 11) is the major kinase phosphorylating the AMPK activation loop at Thr¹⁷².

Recent epidemiologic studies are linking administration of metformin with reduced incidence, recurrence, and mortality of a variety of cancers in patients with T2DM (66). Although epidemiologic associations do not establish causation, they provide an important line of evidence that supports the need for mechanistic studies. The protective effects of metformin in human cancers could be mediated by direct suppression of mitogenic signaling through AMPK-dependent and/or AMPK-independent pathways. It is well established that metformin inhibits mTORC1 activation in a variety of cancer cell types (67). At low concentrations of metformin, the inhibitory effect on mTORC1 is prominent in cells incubated in medium containing physiologic concentrations of glucose (68). Studies in vitro demonstrated that AMPK inhibits mTORC1 activation at several levels: (i) AMPK stimulates TSC2 function via phosphorylation on Ser¹³⁴⁵ (69), leading to accumulation of RHEB-GDP (the inactive form) and thereby to inhibition of mTORC1; (ii) AMPK directly phosphorylates RAPTOR (on Ser⁷²² and Ser⁷⁹²), which disrupts its association with mTOR, leading to dissociation of mTORC1 (70); (iii) metformin has also been proposed to inhibit mTORC1 via AMPK-independent pathways, targeting RAG GTPases or cyclin D1 but these effects were elicited at very high concentrations. Direct effects of metformin at clinically relevant doses are of great significance because they imply that this drug will be a useful anticancer agent not only for patients with T2DM but also for nondiabetic patients.

Although metformin inhibits the mTORC1/S6K axis, its effects on feedback loops regulating AKT and ERK activation are very different from rapalogs, active-site mTOR inhibitors, and dual PI3K/mTOR inhibitors (25). For example, metformin, in contrast to rapamycin, did not overstimulate AKT phosphorylation on Ser⁴⁷³ although both rapamycin and metformin strongly inhibited the mTORC1/S6K axis. Although the precise mechanism explaining this difference is not fully understood, it is relevant that AMPK directly phosphorylates IRS-1 on Ser⁷⁹⁴, a site that interferes with PI3K activation (71, 72). In addition, mTORC2 phosphorylates AKT not only at Ser⁴⁷³ but also at the turn motif site (Thr⁴⁵⁰) of AKT required for its proper folding (41, 42). A recent study demonstrated that a high level of cellular ATP levels is required to maintain the integrity of mTORC2-mediated phosphorylation of AKT on the turn motif Thr⁴⁵⁰ site (73). Because metformin inhibits mitochondrial ATP production, it is conceivable that a small decline in ATP levels induced by this biguanide interferes with the integrity of mTORC2 and with its ability to phosphorylate AKT at Ser⁴⁷³, another mechanism that would prevent AKT overactivation even when the mTORC1/S6K axis is suppressed.

An important difference between the effects of metformin and mTOR inhibitors is that metformin inhibited rather than overactivated MEK/ERK in response to growth factors (25). A plausible mechanism underlying the inhibitory effect metformin on MEK/ERK activation is suggested by a recent study showing that AMPK phosphorylates BRAF at Ser⁷²⁹ (74). The phosphorylation of this site promotes the association of BRAF with 14–3–3 proteins and disrupts its interaction with the KSR1 scaffolding protein leading to decrease in the activity of the MEK/ERK pathway. Interestingly, ERK signaling was not decreased by AMPK in BRAF-mutant tumors (74). Collectively, these studies in vitro imply that metformin has considerable advantages in promoting mTOR inhibition without unleashing feedback loops that oppose its antiproliferative effects, though these effects are likely depend on cell context and oncogenic mutations. A number of clinical trials in progress, combining metformin with established anticancer agents, will determine whether metformin is useful in cancer therapeutics. Because AMPK appears to prevent tumor development rather than to inhibit advanced malignancies, it is conceivable that metformin will be more useful in chemoprevention rather than in a therapeutic setting.

One of the first indications that cells can be stimulated to reinitiate DNA synthesis through different molecular pathways that act in a combinatorial manner was obtained from studies using multiple growth factors in Swiss 3T3 fibroblasts (75). Subsequent studies substantiated the concept that multiple parallel pathways that cross-talk and converge on key signaling nodes lead to proliferation of both normal and cancer cells. A corollary of this concept is that release of negative feedback loops and consequent compensatory overactivation of promitogenic pathways in response to signal inhibitors can circumvent the mitogenic block imposed by targeting only one pathway. Consequently, the elucidation of the network of feedback loops that regulate signal transduction outputs of complex signaling networks has emerged as an area of fundamental importance for the rational design of effective anticancer combinations of inhibitors. In recent years, it has become apparent that most signaling pathways are controlled by negative feedback loops that fine tune the signaling network and that in many cases, the success of therapies targeting one pathway is thwarted by the compensatory overactivation of upstream pathways that remodeled the network.

Here, we discussed that inhibition of mTOR or PI3K/mTOR induces rapid signaling in a variety of cancer cells through compensatory overactivation of pro-oncogenic and prosurvival pathways mediated by unleashing feedback inhibition of upstream signaling (Figs. 2 and 3). Specifically, rapamycin triggers PI3K activation and AKT phosphorylation at Thr³⁰⁸ and Ser⁴⁷³ via suppression of mTORC1/S6K phosphorylation of IRS-1 and SIN1. In some cancer cells, rapalogs also induce MEK/ERK via PI3K-dependent pathway that could involve RAC/PAK1. Active-site mTOR inhibitors induce PI3K activation and AKT phosphorylation at Thr³⁰⁸ but not at Ser⁴⁷³ most likely via suppression of GRB10-mediated feedback inhibition of insulin/IGF receptors and/or suppression of PKCα negative regulation of EGFR. In turn, dual PI3K/mTOR inhibitors promote robust overactivation of the MEK/ERK pathway, most likely via suppression of GRB10- and mTORC2-mediated feedback loops.

Chronic exposure to the same agents initiates a program of FOXO-mediated transcriptional derepression leading to increased expression of multiple TRKs, including HER3, IGFR, and insulin receptor. The distinction between short-term and long-term consequences in response to inhibitors is important for defining strategies to overcome drug resistance, including the dosing schedule of the drug and the pathways that should be cotargeted for optimal response. It is reasonable to propose that rapid overactivation of ERK signaling will be important in mediating resistance when strong but intermittent inhibition of mTOR is used. In this case, inhibition of mTOR should be associated with MEK inhibition. Reciprocally, slow FOXO-mediated transcriptional derepression of TRK expression is likely to be important when mTOR or dual PI3K/mTOR inhibitors are administrated to produce constant inhibition of these targets. In this case, inhibitors of EGFR and HER2 (e.g., lapatinib) and/or IGFR might be the drugs of choice for combinatory therapy (i.e., mTOR or dual PI3K/mTOR inhibitors with either lapatinib or IGFR inhibitor).

Although metformin inhibits stimulation of the mTORC1/S6K axis in vitro, its effects on feedback loops regulating AKT and ERK activation are very different from rapalogs, active-site mTOR inhibitors or dual PI3K/mTOR inhibitors. Metformin, in contrast to rapamycin, did not overstimulate AKT phosphorylation on Ser⁴⁷³. An important difference between the effects of metformin and active-site mTOR inhibitors is that metformin inhibited rather than overactivated the MEK/ERK pathway in several cell types in response to growth factors. Collectively, these studies imply that metformin has considerable advantages in promoting mTOR inhibition without unleashing feedback loops that oppose its antiproliferative effects, though these effects are likely to depend on cell context and oncogenic mutations.

In conclusion, the elucidation of the feedback loops that regulate the outputs of signaling networks has emerged as an area of fundamental importance for the rationale design of effective anticancer combinations of inhibitors. Here, we reviewed pathways in cancer cells that undergo compensatory overactivation in response to inhibitors that suppress feedback inhibition of upstream signaling. Developing appropriate strategies or regimens that maximize the effect on tumor cells and spare normal cells will be also therapeutically important. This article highlights the importance of discovering signaling feedbacks to anticipate mechanisms of tumor resistance to new drugs.

The authors declare no conflicts of interest.

The work in the laboratory of E. Rozengurt is supported by NIH grants P30DK41301, P01CA163200, and R01DK100405, Department of Veterans Affair Grant 1I01BX001473, and funds from the endowed Ronald S. Hirschberg Chair of Pancreatic Cancer Research (http://www.nih.gov/).